|
|
|
|
|
|
Sponsored by: |
Genentech |
Information provided by: | Genentech |
ClinicalTrials.gov Identifier: | NCT00063154 |
The purpose of this study is to determine if the study drug pertuzumab is effective in treating patients with advanced lung cancer that has recurred following prior chemotherapy.
Condition | Intervention | Phase |
Non-Small Cell Lung Cancer |
Drug: rhuMAb 2C4 (pertuzumab) |
Phase II |
MedlinePlus related topics: | Cancer Lung Cancer |
ChemIDplus related topics: | Pertuzumab |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II, Open-Label, Multicenter Study to Evaluate the Effect of Tumor-Based HER2 Activation on the Efficacy of rhuMAb 2C4 (Pertuzumab) in Subjects With Recurrent Non-Small Cell Lung Cancer |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Arizona | |||||
Arizona Cancer Center | |||||
Scottsdale, Arizona, United States, 85258 | |||||
Arizona Cancer Center | |||||
Tucson, Arizona, United States, 85724-5024 | |||||
United States, California | |||||
University of California Davis Cancer Center | |||||
Sacramento, California, United States, 95817 | |||||
Cedars-Sinai Comprehensive Cancer Center | |||||
Los Angeles, California, United States, 90048 | |||||
United States, Massachusetts | |||||
Dana Farber Cancer Institute | |||||
Boston, Massachusetts, United States, 02115 | |||||
United States, New York | |||||
Memorial-Sloan Kettering Cancer Center | |||||
New York, New York, United States, 10021-6007 | |||||
United States, Tennessee | |||||
Vanderbilt Ingram Cancer Center | |||||
Nashville, Tennessee, United States, 37232-5536 | |||||
United States, Texas | |||||
University of Texas MD Anderson Cancer Center | |||||
Houston, Texas, United States, 77030-4009 |
Genentech |
Study ID Numbers: | TOC2572g |
First Received: | June 20, 2003 |
Last Updated: | August 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00063154 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|